Performance share rights issue

Capital Change Notice


2202168 | 6207255v1


Section 1: Issuer information
Name of issuer Blis Technologies Limited
NZX ticker code BLT
Class of financial product Options to acquire ordinary
shares
ISIN (If unknown, check on NZX website) NZBLTE0002S8
Currency NZD
Section 2: Capital change details
Number issued/acquired/redeemed 3,270,000 options (convertible
into ordinary shares on a 1:1
ratio)
Nominal value (if any) N/A
Issue/acquisition/redemption price per security No amount is payable for the
options. The options have an
exercise price of $0.072 per
share.
Nature of the payment (for example, cash or other
consideration)
Non-cash consideration for
services provided by the
holders of the options, being
members of BLT's senior
management team.
Amount paid up (if not in full) N/A
Percentage of total class of Financial Products
issued/acquired/redeemed/ (calculated on the number of
Financial Products of the Class, excluding any Treasury Stock,
in existence)
If on vesting, all options are
exercised, 0.2567% of the
ordinary shares in BLT (based
on the number of ordinary
shares currently on issue).
For an issue of Convertible Financial Products or Options, the
principal terms of Conversion (for example the Conversion
price and Conversion date and the ranking of the Financial
Product in relation to other Classes of Financial Product) or the
Option (for example, the exercise price and exercise date)
The holder's options will vest in
three years on the
achievement of certain
financial conditions being met
and the continuous
employment of each option
holder.
Reason for issue/acquisition/redemption and specific authority
for issue/acquisition/redemption/ (the reason for change must
be identified here)
Issue of options for retention
and incentivising the senior
management team.
Total number of Financial Products of the Class after the
issue/acquisition/redemption/Conversion (excluding Treasury
Stock) and the total number of Financial Products of the Class
held as Treasury Stock after the issue/acquisition/redemption.
5,944,000 options
1,273,801,599 ordinary shares
In the case of an acquisition of shares, whether those shares
are to be held as treasury stock
N/A

2202168 | 6207255v1

Specific authority for the issue, acquisition, or redemption,
including a reference to the rule pursuant to which the issue,
acquisition, or redemption is made
Directors' resolution dated 10
September 2021 approving
issue under Listing Rule 4.6.1
Terms or details of the issue, acquisition, or redemption (for
example: restrictions, escrow arrangements)
Options are issued on the
terms of the directors'
resolution. They do not vest
for 3 years and only on certain
conditions being met.
Date of issue/acquisition/redemption 10 September 2021
Section 3: Authority for this announcement and contact person
Name of person

authorised to make this announcement
Richard Wingham (CFO, BLT)
Contact person for this announcement
Richard Wingham (CFO, BLT)
Contact phone number
021 284 0446
Contact email address
richard.wingham@blis.co.nz
Date of release through MAP

14 September 2021

---

14 September 2021
Performance share rights issue
Blis Technologies Limited (Company) has issued performance share rights for no consideration to
certain members of its senior leadership and senior management teams. The performance share
rights were approved by the directors of the Company on 10 September 2021.
The performance rights give the holder options to receive ordinary shares in the Company, which
may be exercised if the performance rights vest. The vesting period is three years from the date the
performance rights are granted, and vesting of the performance rights is conditional on the
Company meeting certain compound annual growth targets set by the board in respect of its share
price and net profit, and the continuous employment of the relevant holder.

Ends

For further information, please contact:

Geoff Plunket
Chair
+64 21 229 8886


About Blis Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath),
immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand
and in Australia, Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at
www.blis.co.nz.

Website: www.unconditionalskin.com
Instagram: @unconditionalskin #BLISQ24 #USC
Facebook: @unconditionalskin